Taiwan FDA registration f3d7c92b90bf912ad1f33309875df7ab
Prinmos CLC385 fully automated glycoglogen detection kit
TW: 普林莫斯CLC385全自動化醣化血色素檢測試劑組
Taiwan·Risk Class 2·Trinity Biotech (Primus Corporation dba Trinity Biotech)·Registered Jan 05, 2006 – Jan 05, 2016CancelledRegistration details
- Analysis ID
- f3d7c92b90bf912ad1f33309875df7ab
- Customs Code
- DHA00601582500
Company information
- Manufacturer Country
- United States
- Authorized Representative
- PROGRESSIVE GROUP INC.
Product details
- Intended Use
- It is used in the Prinsmuth CLC385 automatic glycosylated hemoglobin analysis system to quantify glycosylated hemoglobin in vitro diagnostic test by high-pressure liquid chromatography in normal or diabetic patients.
- Product Type (Level 1)
- B Hematology, pathology, and genetics
- Product Type (Level 2)
- B.7470 Analysis of glycosylated hemoglobin
- Import Information
- import
Dates and status
- Registration Date
- Jan 05, 2006
- Expiry Date
- Jan 05, 2016
- Cancellation Date
- May 28, 2018
Cancellation information
- Status
- Logged out
- Reason
- 許可證已逾有效期
About this record
Access comprehensive regulatory information for Prinmos CLC385 fully automated glycoglogen detection kit in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number f3d7c92b90bf912ad1f33309875df7ab and manufactured by Trinity Biotech (Primus Corporation dba Trinity Biotech). The authorized representative in Taiwan is PROGRESSIVE GROUP INC..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices